Eikon Therapeutics EIKN Insider Ownership

Updated Oct 10, 2026

Across the past 12 months, open-market trades by Eikon Therapeutics insiders were all purchases, totaling $47.15 million (2.65Mn shares).

• By number of insiders, Eikon Therapeutics saw 4 insiders buy on the open market over the past 12 months and none sell.
• Among EIKN's insiders, Column Group IV GP, LP (10% owner) was the top open-market buyer in the past 12 months, with $39.15 million of stock purchased (2.21Mn shares) and the latest purchase on September 3, 2026.
• In transactions other than open-market trades, Eikon Therapeutics insiders acquired 13.62Mn shares through option exercises and conversions over the past 12 months.
• Business Quant data puts insider holdings in EIKN at 9.88Mn shares across insiders' latest Form 4 filings, up 0.91% from 9.79Mn shares at the end of Q2 2026.
• Direct holdings account for 111.11K shares (1.12%) of EIKN's insider total, and indirect holdings through trusts, partnerships and family members for 9.77Mn shares (98.88%).
• Holdings in Eikon Therapeutics stock are reported by 5 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Eikon Therapeutics' three largest insider shareholders, based on their latest Form 4 filings, are Column Group IV GP, LP (10% owner, 5.87Mn shares), Josh Wolfe (Director and 10% owner, 2.29Mn shares) and Foresite Capital Management IV, LLC (10% owner, 1.32Mn shares).
• The holding of Column Group IV GP, LP makes up 59.41% of all shares held by Eikon Therapeutics insiders.
• Institutions accounted for 48.94% of EIKN's outstanding shares in Q2 2026, insiders about 18.24% per their latest Form 4 filings, and other investors, including the public, about 32.82%.
• Over the trailing 12 months, 11 insiders reported transactions in EIKN stock across 14 Form 4 filings.
• These insider figures for Eikon Therapeutics are based on Form 4 filings through September 8, 2026.